Genscript Biotech Corporation
GNNSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $594 | $840 | $626 | $511 |
| % Growth | -29.2% | 34.2% | 22.4% | – |
| Cost of Goods Sold | $322 | $430 | $322 | $208 |
| Gross Profit | $272 | $410 | $304 | $283 |
| % Margin | 45.8% | 48.8% | 48.6% | 55.3% |
| R&D Expenses | $54 | $434 | $390 | $358 |
| G&A Expenses | $114 | $213 | $182 | $135 |
| SG&A Expenses | $202 | $388 | $351 | $302 |
| Sales & Mktg Exp. | $88 | $80 | $168 | $168 |
| Other Operating Expenses | $7 | $4 | $1 | -$9 |
| Operating Expenses | $263 | $825 | $742 | $652 |
| Operating Income | $9 | -$416 | -$436 | -$368 |
| % Margin | 1.6% | -49.5% | -69.7% | -72.1% |
| Other Income/Exp. Net | -$180 | $143 | -$4 | -$149 |
| Pre-Tax Income | -$171 | -$351 | -$432 | -$517 |
| Tax Expense | $3 | $4 | -$4 | $1 |
| Net Income | $2,962 | -$95 | -$227 | -$359 |
| % Margin | 498.2% | -11.4% | -36.3% | -70.2% |
| EPS | 1.4 | -0.045 | -0.11 | -0.18 |
| % Growth | 3,190.5% | 58.8% | 38.9% | – |
| EPS Diluted | 1.36 | -0.045 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 2,121 | 2,108 | 2,097 | 2,031 |
| Weighted Avg Shares Out Dil | 2,178 | 2,109 | 2,097 | 2,031 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $73 | $13 | $3 |
| Interest Expense | $8 | $28 | $13 | $2 |
| Depreciation & Amortization | $61 | $74 | $64 | $48 |
| EBITDA | $70 | -$249 | -$355 | -$466 |
| % Margin | 11.8% | -29.6% | -56.7% | -91.1% |